«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2024 24

Page:

4569-4579

Research Field:

Publishing date:

Info

Title:

Chinese expert consensus on diagnosis and treatment of ovarian cancer in the elderly

Author(s):

LIU Junxiu¹; CHEN Yili¹; GAO Guolan²; CUI Heng³; ZHANG Ping⁴

Gynecology Branch of the Chinese Society of Gerontology and Geriatrics (1.The First Affiliated Hospital of Sun Yat-sen University,Guangdong Guangzhou 510080£¬China;2.West China Second Hospital of Sichuan University,Sichuan Chengdu 610016£¬China;3.Peking University People's Hospital,Beijing 100044£¬China;4.Zhejiang Cancer Hospital,Zhejiang Hangzhou 310022,China.)

Keywords:

ovarian cancer; elderly women; China; expert consensus

PACS:

R737.31

DOI:

10.3969/j.issn.1672-4992.2024.24.001

Abstract:

Ovarian cancer is one of the most common gynecological malignancies.Elderly patients with ovarian cancer often have multiple complications,poor tolerance to surgery and chemotherapy,and poor overall prognosis.Increasing age is one of the independent risk factors for reduced survival in elderly patients with ovarian cancer.With the continuous aggravation of the aging of the population,it is urgent to develop effective diagnosis and treatment plans for elderly patients.Therefore,in order to standardize the diagnosis and treatment of ovarian cancer in elderly Chinese women,the Gynecology Branch of the Chinese Society of Gerontology and Geriatrics organized experts to form the following Chinese expert consensus based on evidence-based medicine and combined with clinical diagnosis and treatment experience to guide clinical practice.

References:

£Û1£ÝFERLAY J,ERVIK M,LAM F,et al.Global cancer observatory:Cancer today.Lyon,France:International agency for research on cancer£ÛZ/OL£Ý.£Û2024-07-10£Ý.https://gco.iarc.who.int/today.
£Û2£ÝZHENG RS,CHEN R,HAN BF,et al.Cancer incidence and mortality in China,2022£ÛJ£Ý.Chin J Oncol,2024,46(3):221-231.
£Û3£ÝTEW WP.Ovarian cancer in the older woman£ÛJ£Ý.J Geriatr Oncol,2016,7(5):354-361.
£Û4£Ý¹ú¼Òͳ¼Æ¾Ö.µÚÆß´ÎÈ«¹úÈË¿ÚÆղ鹫±¨£ÛZ/OL£Ý.(2021-05-11)£Û2021-12-10£Ý.http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html. National Bureau of Statistics.The official report of China's seventh national population census £ÛZ/OL£Ý.(2021-05-11)£Û2021-12-10£Ý.http://www.stats.gov.cn/tjsj/tjgb/rkpcgb/qgrkpcgb/202106/t20210628_1818824.html.
£Û5£ÝÊ¢ÒàÄÐ,¹Ë´óÄÐ.¸ÅÂÊÈË¿ÚÔ¤²â·½·¨¼°ÆäÓ¦Ó᪡ª¡¶ÊÀ½çÈË¿ÚÕ¹Íû¡·¸ÅÂÊÈË¿ÚÔ¤²â·½·¨¼ò½é£ÛJ£Ý.ÈË¿Úѧ¿¯,2020,42(5):31-46. SHENG Yinan,GU Danan.Probabilistic population forecasting methods and their applications-introduction to probabilistic population forecasting methods in world population prospects £ÛJ£Ý.Population Journal,2020,42(5):31-46.
£Û6£ÝÕÅð©,Ò¢Á¼Çå.ÀÏÄêÂѳ²°©µÄÖÎÁÆ£ÛJ£Ý.ÀÏÄêҽѧÓë±£½¡,2019,25(03):288-291. ZHANG Hao,YAO Liangqing.Treatment of ovarian cancer in the elderly £ÛJ£Ý.Geriatrics & Health Care,2019,25(03):288-291.
£Û7£ÝÓàÃô»ª,µÒÎÄ.ÀÏÄêÂѳ²°©µÄÕïÖιؼüÎÊÌâ£ÛJ£Ý.ÀÏÄêҽѧÓë±£½¡,2019,25(03):277-279. YU Minhua,DI Wen.Key issues in the diagnosis and treatment of elderly ovarian cancer £ÛJ£Ý.Geriatrics & Health Care,2019,25(03):277-279.
£Û8£ÝÖйú¿¹°©Ð­»á¸¾¿ÆÖ×ÁöרҵίԱ»á.Âѳ²¶ñÐÔÖ×ÁöÕï¶ÏÓëÖÎÁÆÖ¸ÄÏ£¨2021Äê°æ£©£ÛJ£Ý.Öйú°©Ö¢ÔÓÖ¾,2021,31(06):490-500. CGCS.Guidelines for diagnosis and treatment of ovarian malignant tumors (2021 edition) £ÛJ£Ý.China Oncology,2021,31(06):490-500.
£Û9£ÝKING MC,MARKS JH,MANDELL JB.Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2£ÛJ£Ý.Science,2003,302(5645):643-646.
£Û10£Ý¶­ÑÓÀÚ,Íõ½¨¶«,ÍõÓñ¶«,µÈ.Ô¤·ÀÐÔÊäÂѹÜÇгýÊõµÄÖйúר¼Ò¹²Ê¶£¨2021Äê°æ£©£ÛJ£Ý.ÖйúʵÓø¾¿ÆÓë²ú¿ÆÔÓÖ¾,2021,37(08):826-831. DONG Yanlei,WANG Jiandong,WANG Yudong,et al.Chinese expert consensus on prophylactic bilateral salpingectomy (2021) £ÛJ£Ý.Chinese Journal of Practical Gynecology and Obstetrics,2021,37(08):826-831.
£Û11£ÝNational Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:Ovarian cancer continue including fallopian tube cancer and primary peritoneal Cancer.Version 2£ÛZ£Ý.2024.
£Û12£ÝÖлªÒ½Ñ§»á¸¾¿ÆÖ×Áöѧ·Ö»á.Öйú¸¾¿ÆÖ×ÁöÁÙ´²Êµ¼ùÖ¸ÄÏ£¨µÚ7°æ£©£ÛS£Ý.2023. CSGO.Clinical practice guidelines for gynecological tumors in China (version 7) £ÛS£Ý.2023.
£Û13£ÝÖйúÈý¼¶¸¾²ú¿ÆÒ½Ôº/¸¾Ó×±£½¡ÔºÁªÃ˸¾¿ÆÖ×ÁöÒÅ´«×ÉѯЭ×÷×é,Öйú¿¹°©Ð­»áÖÐÎ÷ÕûºÏ×Ó¹¬ÄÚĤ°©×¨ÒµÎ¯Ô±»á.¸¾¿ÆÖ×ÁöÒÅ´«×Éѯר¼Ò¹²Ê¶£¨2023Äê°æ£©£ÛJ£Ý.Öйú°©Ö¢ÔÓÖ¾,2023,33(11):1041-1064. Gynecological Oncology from Gynecologic Oncology Genetic Counseling Collaboration Group,Chinese Tertiary Obstetrics and Gynecology Hospital/Materning and Child Healthcare Hospital Alliance,and Integrated Chinese and Western Endometrial Cancer Professional Committee,Chinese Anti-Cancer Association.Expert consensus on genetic counseling in gynecological oncology (2023 edition) £ÛJ£Ý.China Oncology,2023,33(11):1041-1064.
£Û14£Ý¶Å³ÌÎ,¾¸Ðñ,¶ÎΰÀö.¸¾¿ÆÖ×Áö±êÖ¾ÎïÓ¦ÓÃר¼Ò¹²Ê¶£ÛJ£Ý.ɽ¶«´óѧѧ±¨(ҽѧ°æ),2018,56(10):3-8. DU Lutao,JING Xu,DUAN Weili.Expert consensus on the application of gynecological tumor markers£ÛJ£Ý.Journal of Shandong University (Health Sciences),2018,56(10):3-8.
£Û15£ÝHERMENS M,VAN ALTENA AM,NIEBOER TE,et al.Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis:the ENOCA population-based cohort study£ÛJ£Ý.Am J Obstet Gynecol,2020,223(1):101-107.
£Û16£ÝSUIDAN RS,RAMIREZ PT,SARASOHN DM,et al.A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer£ÛJ£Ý.Gynecol Oncol,2017,145(1):27-31.
£Û17£ÝAVESANI G,ARSHAD M,LU H,et al.Radiological assessment of peritoneal cancer index on preoperative CT in ovarian cancer is related to surgical outcome and survival£ÛJ£Ý.Radiol Med,2020,125(8):770-776.
£Û18£ÝÖлªÈËÃñ¹²ºÍ¹ú¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»á.Âѳ²°©ÕïÁÆÖ¸ÄÏ£ÛZ/OL£Ý.£Û2024-07-10£Ý.http://www.nhc.gov.cn. National Health Commission of the People's Republic of China.Guidelines for diagnosis and treatment of ovarian cancer £ÛZ/OL£Ý.£Û2024-07-10£Ý.http://www.nhc.gov.cn.
£Û19£ÝFAGOTTI A,FERRANDINA G,FANFANI F,et al.A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma:a pilot study£ÛJ£Ý.Ann Surg Oncol,2006,13(8):1156-1161.
£Û20£ÝNational Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology:Older adult oncology.Version 1£ÛS£Ý.2024.
£Û21£ÝINGRAM SS,SEO PH,MARTELL RE,et al.Comprehensive assessment of the elderly cancer patient:the feasibility of self-report methodology£ÛJ£Ý.J Clin Oncol,2002,20(3):770-775.
£Û22£ÝÖìÃùÀ×,»ÆÓî¹â,ÁõÏþºì,µÈ.ÀÏÄ껼ÕßΧÊÖÊõÆÚ¹ÜÀí±±¾©Ð­ºÍҽԺר¼Ò¹²Ê¶£ÛJ£Ý.ЭºÍҽѧÔÓÖ¾,2018,9(01):36-41. ZHU Minglei,HUANG Yuguang,LIU Xiaohong,et al.Expert consensus from Peking Union Medical College Hospital on perioperative management of elderly patients £ÛJ£Ý.Medical Journal of Peking Union Medical College Hospital,2018,9(01):36-41.
£Û23£ÝPRAUSE G,RATZENHOFER-COMENDA B,PIERER G,et al.Can ASA grade or Goldman's cardiac risk index predict peri-operative mortality? A study of 16,227 patients£ÛJ£Ý.Anaesthesia,1997,52(3):203-206.
£Û24£Ý³Â¾ü,³µ¹úÎÀ,Ëï´óÇ¿,µÈ.ÀÏÄê·Î°©Íâ¿ÆÖÎÁÆÖйúר¼Ò¹²Ê¶£¨2022°æ£©£ÛJ£Ý.Öйú·Î°©ÔÓÖ¾,2023,26(02):83-92. CHEN Jun,CHE Guowei,SUN Daqiang,et al.Consensus of Chinese experts on surgical treatment of lung cancer in the elderly (2022 edition) £ÛJ£Ý.Chinese Journal of Lung Cancer,2023,26(02):83-92.
£Û25£ÝÕŹú»ª,ÍõÇ¿,ÕÔÀöÔÆ,µÈ.ÖйúÀÏÄê½áÖ±³¦Ö×Áö»¼ÕßΧÊÖÊõÆÚ¹ÜÀíר¼Ò¹²Ê¶(2020°æ)£ÛJ£Ý.Öлª½áÖ±³¦¼²²¡µç×ÓÔÓÖ¾,2020,9(04):325-334. ZHANG Guohua,WANG Qiang,ZHAO Liyun,et al.Expert consensus on perioperative management of elderly patients with colorectal cancer in China (2020 edition) £ÛJ£Ý.Chinese Journal of Colorectal Diseases (Electronic Edition),2020,9(04):325-334.
£Û26£ÝHERTLEIN L,KIRSCHENHOFER A,FURST S,et al.Malnutrition and clinical outcome in gynecologic patients£ÛJ£Ý.Eur J Obstet Gynecol Reprod Biol,2014,174:137-140.
£Û27£ÝÖлªÒ½Ñ§»á³¦Í⳦ÄÚÓªÑøѧ·Ö»á¡°ÓªÑø·çÏÕ-ÓªÑø²»×ã-Ö§³Ö-½á¾Ö-³É±¾/Ч¹û±È£¨NUSOC£©¡±¶àÖÐÐÄÊý¾Ý¹²ÏíЭ×÷×é.ÓªÑø·çÏÕ¼°ÓªÑø·çÏÕɸ²é¹¤¾ßÓªÑø·çÏÕɸ²é2002ÁÙ´²Ó¦ÓÃר¼Ò¹²Ê¶£¨2018°æ£©£ÛJ£Ý.ÖлªÁÙ´²ÓªÑøÔÓÖ¾,2018,26£¨3£©:131-135. Multi Center Data Sharing Collaboration Group of NUSOC.Expert consensus on progress in the clinical application of nutritional risk and nutritional risk screening tool 2002 nutritional risk screening 2002 (2018 edition) £ÛJ£Ý.Chinese Journal of Clinical Nutrition,2018,26£¨3£©:131-135.
£Û28£ÝÕÅÒÃ,ÅÓÏþÑà,À÷,µÈ.ÀÏÄ긾¿Æ»¼ÕßΧÊÖÊõÆÚ¹ÜÀíÖйúר¼Ò¹²Ê¶£¨2024Äê°æ£©£ÛJ£Ý.ÖйúʵÓø¾¿ÆÓë²ú¿ÆÔÓÖ¾,2024,40(05):541-548. ZHANG Yi,PANG Xiaoyan,LI Meifang,et al.Chinese expert consensus on perioperative management of elderly gynecological patients (2024 edition) £ÛJ£Ý.Chinese Journal of Practical Gynecology and Obstetrics,2024,40(05):541-548.
£Û29£ÝJIANG C,LI Z.Performance validation of the Mayo triage algorithm applied to individualize surgical management of advanced epithelial ovarian cancer£ÛJ£Ý.Gynecol Oncol,2021,162(2):339-344.
£Û30£ÝNARASIMHULU DM,KUMAR A,WEAVER AL,et al.Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer£ÛJ£Ý.Gynecol Oncol,2019,155(1):58-62.
£Û31£ÝALETTI GD,DOWDY SC,PODRATZ KC,et al.Relationship among surgical complexity,short-term morbidity,and overall survival in primary surgery for advanced ovarian cancer£ÛJ£Ý.Am J Obstet Gynecol,2007,197(6):676.e1-7.
£Û32£ÝKUMAR A,JANCO JM,MARIANI A,et al.Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer£ÛJ£Ý.Gynecol Oncol,2016,140(1):15-21.
£Û33£ÝVON GRUENIGEN VE,HUANG HQ,BEUMER JH,et al.Chemotherapy completion in elderly women with ovarian,primary peritoneal or fallopian tube cancer-An NRG oncology/Gynecologic Oncology Group study£ÛJ£Ý.Gynecol Oncol,2017,144(3):459-467.
£Û34£ÝPIGNATA S,BREDA E,SCAMBIA G,et al.A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer.A Multicentre Italian Trial in Ovarian cancer (MITO-5) study£ÛJ£Ý.Crit Rev Oncol Hematol,2008,66(3):229-236.
£Û35£ÝPIGNATA S,SCAMBIA G,KATSAROS D,et al.Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7):a randomised,multicentre,open-label,phase 3 trial£ÛJ£Ý.Lancet Oncol,2014,15(4):396-405.
£Û36£ÝFALANDRY C,ROUSSEAU F,MOURET-REYNIER MA,et al.Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer:A GINECO/GCIG randomized clinical trial£ÛJ£Ý.JAMA Oncol,2021,7:853-861.
£Û37£Ý¸ßÇìÀÙ,¿×±±»ª,ÒüÈçÌú,µÈ.PARPÒÖÖƼÁÖÎÁƸ´·¢ÐÔÂѳ²°©×¨¼Ò¹²Ê¶£ÛJ£Ý.ÏÖ´ú¸¾²ú¿Æ½øÕ¹,2018,27(10):721-725. GAO Qinglei,KONG Beihua,YIN Rutie,et al.Expert consensus on PARP inhibitor in the treatment of recurrent ovarian cancer £ÛJ£Ý.Progress in Obstetrics and Gynecology,2018,27(10):721-725.
£Û38£ÝÖÜçù,ÎâС»ª,Áõ¼Ìºì,µÈ.ÖйúÂѳ²ÉÏƤÐÔ°©Î¬³ÖÖÎÁÆר¼Ò¹²Ê¶£¨2020)£ÛJ£Ý.ÖйúʵÓø¾¿ÆÓë²ú¿ÆÔÓÖ¾,2020,36(03):234-238. ZHOU Qi,WU Xiaohua,LIU Jihong,et al.Expert consensus on maintenance treatment of epithelial ovarian cancer in China (2020) £ÛJ£Ý.Chinese Journal of Practical Gynecology and Obstetrics,2020,36(03):234-238.
£Û39£ÝLIPOSITS G,LOH KP,SOTO-PEREZ-DE-CELIS E,et al.PARP inhibitors in older patients with ovarian and breast cancer:Young International Society of Geriatric Oncology review paper£ÛJ£Ý.J Geriatr Oncol,2019,10(2):337-345.
£Û40£ÝLAFARGUE CJ,DAL MOLIN GZ,SOOD AK,et al.Exploring and comparing adverse events between PARP inhibitors£ÛJ£Ý.Lancet Oncol,2019,20(1):e15-e28.
£Û41£ÝµËæÃ,·ëÑÞÁá,»Æç²µ¤,µÈ.º¬±´·¥Öéµ¥¿¹ÁªºÏ·½°¸ÖÎÁÆÍíÆÚÂѳ²°©µÄÑо¿½øÕ¹£ÛJ£Ý.°©Ö¢,2022,41(03):97-106. DENG Ting,FENG Yanling,HUANG Qidan,et al.Research progress on combination therapy with bevacizumab for advanced ovarian cancer £ÛJ£Ý.Chinese Journal of Cancer,2022,41(03):97-106.
£Û42£ÝLUM C,STEER CB.Targeted therapies in the management of ovarian cancer:A focus on older patients£ÛJ£Ý.Drugs Aging,2017,34(11):821-831.
£Û43£ÝGODBY RC,JOHNSON DB,WILLIAMS GR.Immunotherapy in older adults with cancer£ÛJ£Ý.Curr Oncol Rep,2019,21(7):56.
£Û44£ÝELIAS R,ODEJIDE O.Immunotherapy in older adults:A checkpoint to palliation£ÛJ£Ý.Am Soc Clin Oncol Educ Book,2019,39:e110-e120.
£Û45£ÝTSUKITA Y,TOZUKA T,KUSHIRO K,et al.Immunotherapy or chemoimmunotherapy in older adults with advanced non-small cell lung cancer£ÛJ£Ý.JAMA Oncol,2024,10(4):439-447.
£Û46£ÝJOHNS AC,YANG M,WEI L,et al.Risk factors for immune checkpoint inhibitor immunotherapy toxicity among older adults with cancer£ÛJ£Ý.Oncologist,2023,28(8):e625-e632.
£Û47£ÝëÄÏÈô,½ªÎ°.PD-1/PD-L1ÃâÒßÒÖÖƼÁÖÎÁÆÂѳ²°©µÄÁÙ´²Ó¦ÓýøÕ¹£ÛJ£Ý.¹ú¼Ê¸¾²ú¿ÆѧÔÓÖ¾,2021,48(06):605-609. MAO Ruonan,JIANG Wei.Progress in the clinical application of PD-1/PD-L1 inhibitor in the treatment of ovarian neoplasms £ÛJ£Ý.Journal of International Obstetrics and Gynecology,2021,48(06):605-609.
£Û48£ÝHAMANISHI J,MANDAI M,IKEDA T,et al.Safety and antitumor activity of anti-PD-1 antibody,nivolumab,in patients with platinum-resistant ovarian cancer£ÛJ£Ý.J Clin Oncol,2015,33(34):4015-4022.
£Û49£ÝHAMANISHI J,TAKESHIMA N,KATSUMATA N,et al.Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer:Open-label,randomized trial in Japan (NINJA)£ÛJ£Ý.J Clin Oncol,2021,39(33):3671-3681.
£Û50£ÝVARGA A,PIHA-PAUL S,OTT PA,et al.Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer:Analysis of KEYNOTE-028£ÛJ£Ý.Gynecol Oncol,2019,152(2):243-250.
£Û51£ÝLIU JF,GORDON M,VENERIS J,et al.Safety,clinical activity and biomarker assessments of atezolizumab from a phase I study in advanced/recurrent ovarian and uterine cancers£ÛJ£Ý.Gynecol Oncol,2019,154(2):314-322.
£Û52£Ý¿×±±»ª,Áõ¼Ìºì,Òó°®¾ü,µÈ.¸¾¿ÆÖ×ÁöÃâÒß¼ì²éµãÒÖÖƼÁÁÙ´²Ó¦ÓÃÖ¸ÄÏ£¨2023°æ£©£ÛJ£Ý.ÏÖ´ú¸¾²ú¿Æ½øÕ¹,2023,32(05):321-348. KONG Beihua,LIU Jihong,YIN Aijun,et al.Clinical application guidelines for immune checkpoint inhibitors in gynecological tumors (2023 edition) £ÛJ£Ý.Progress in Obstetrics and Gynecology,2023,32(05):321-348.
£Û53£ÝCHAN KKL,NGU SF,CHU MMY,et al.Tamoxifen use in recurrent ovarian cancer in a Chinese population:A 15 -year clinical experience in a tertiary referral center£ÛJ£Ý.Asia Pac J Clin Oncol,2021,17(4):338-342.
£Û54£ÝMARCHETTI C,DE FELICE F,ERGASTI R,et al.Letrozole in the management of advanced ovarian cancer:an old drug as a new targeted therapy£ÛJ£Ý.Int J Gynecol Cancer,2020,30(7):1058-1064.
£Û55£ÝCOLON-OTERO G,WEROHA SJ,FOSTER NR,et al.Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers£ÛJ£Ý.Gynecol Oncol,2017,146(1):64-68.
£Û56£ÝCOLON-OTERO G,ZANFAGNIN V,HOU X,et al.Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers£ÛJ£Ý.ESMO Open,2020,5(5):e000926.
£Û57£ÝTR¦IDAN O,PROVANSAL M,ABDEDDAIM C,et al.Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression:A GINECO randomized phase II trial (REGOVAR)£ÛJ£Ý.Gynecol Oncol,2022,164(1):18-26.

Memo

Memo:

-

Common functions

Last Update: 1900-01-01